Ignite Creation Date:
2024-05-06 @ 9:28 AM
Last Modification Date:
2024-10-26 @ 12:15 PM
Study NCT ID:
NCT02997202
Status:
COMPLETED
Last Update Posted:
2024-03-15
First Post:
2016-12-01
Brief Title:
A Trial of the FMS-like Tyrosine Kinase 3 FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3Internal Tandem Duplication ITD Acute Myeloid Leukemia AML
Sponsor:
Astellas Pharma Global Development Inc
Organization:
Astellas Pharma Inc
Organization Data
Organization:
Astellas Pharma Inc
Class:
INDUSTRY
Study ID:
2215-CL-0304
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Astellas Pharma Global Development Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Blood and Marrow Transplant Clinical Trials Network | NETWORK |
| National Heart Lung and Blood Institute NHLBI | NIH |